Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Dec;19(12):102686.
doi: 10.1016/j.autrev.2020.102686. Epub 2020 Oct 22.

The NZB/W F1 mouse model for Sjögren's syndrome: A historical perspective and lessons learned

Harini Bagavant  1 , Aleksandra Michrowska  1 , Umesh S Deshmukh  2
Affiliations
Review

The NZB/W F1 mouse model for Sjögren's syndrome: A historical perspective and lessons learned

Harini Bagavant et al. Autoimmun Rev. 2020 Dec.

Abstract

Sjögren's syndrome (SS) is a chronic rheumatic autoimmune disorder affecting multiple organ systems. The clinical findings in SS patients show considerable heterogeneity and overlap with other autoimmune diseases. In addition, the autoimmune response in SS initiates several years before the appearance of clinical symptoms. Thus, understanding the pathogenic mechanisms involved in the disease process have been a challenge. Several animal model systems of SS-like disease have been developed to overcome these issues. The New Zealand Black (NZB) x New Zealand White (NZW) F1 (NZB/W F1) mouse represents the first spontaneous mouse model of SS. In this review, we provide a historical perspective and detailed description of this mouse model focusing on exocrine gland histopathology, autoantibody populations, and glandular dysfunction. Considering that NZB/W F1 mice also develop a systemic lupus erythematosus (SLE)-like disease, this mouse model mimics the clinical presentation of polyautoimmunity seen in a sizable subset of SS patients. It is plausible that such patients will require distinct therapeutic interventions necessary to treat both SLE and SS. Therefore, the NZB/W F1 mouse is a powerful tool to decipher pathogenic mechanisms involved in SS related polyautoimmunity and develop appropriate therapeutic strategies.

Keywords: Lupus; Mouse; NZB/W F1; Polyautoimmunity; Salivary gland; Sjögren's syndrome.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.. Salivary gland inflammation in NZB/W F1 female mice at 6–7 months of age.
(A) Representative image of a hematoxylin and eosin-stained submandibular salivary gland showing a large peri-ductal and peri-vascular lymphocytic focus, extending into the gland parenchyma (arrows). Magnification 10×. (B) Immunostaining of the submandibular salivary gland showing the presence of B cells (anti-B220, green) and T cells (anti-CD4, red) within a lymphocytic focus. Magnification 20×.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Sarmiento-Monroy JC, Mantilla RD, Rojas-Villarraga A, et al. Sjögren’s syndrome In: Anaya JM, Shoenfeld Y, Rojas-Villarraga A, et al., editors. Autoimmunity: From Bench to Bedside [Internet]: El Rosario: University Press; 2013. Jul 18, Chapter 28. - PubMed
    1. Restrepo-Jimenez P, Molano-Gonzalez N, Anaya J-M. Geoepidemiology of Sjogren’s syndrome in Latin America. Jt Bone Spine 2019;86:620–6. doi:10.1016/j.jbspin.2019.02.004. - DOI - PubMed
    1. Ramos-Casals M, Brito-Zerón P, Kostov B, Sisó-Almirall A, Bosch X, Buss D, et al. Google-driven search for big data in autoimmune geoepidemiology: Analysis of 394,827 patients with systemic autoimmune diseases. Autoimmun Rev 2015;14:670–9. doi:10.1016/j.autrev.2015.03.008. - DOI - PubMed
    1. Psianou K, Panagoulias I, Papanastasiou AD, de Lastic A-L, Rodi M, Spantidea PI, et al. Clinical and immunological parameters of Sjögren’s syndrome. Autoimmun Rev 2018;17:1053–64. doi:10.1016/j.autrev.2018.05.005. - DOI - PubMed
    1. Vivino F, Bunya VY, Massaro-Giordano G, Johr CR, Giattino SL, Schorpion A, et al. Sjogren’s syndrome: An update on disease pathogenesis, clinical manifestations and treatment. Clin Immunol 2019;203:81–121. doi:10.1016/j.clim.2019.04.009. - DOI - PubMed